BACKGROUND: Ketamine, a non-competitive N-methyl-D: -aspartic acid antagonist, has been widely used for anaesthetic purposes. At sub-anaesthetic dosage, it induces a dissociative state similar to schizophrenia. The discovery of this effect on dissociative state has led to its use as a pharmacological model of schizophrenia and has also been responsible for its illegal use as a recreational drug. Whereas the former has provided invaluable information, the latter has demonstrated that repeated administration of ketamine induces tolerance. Surprisingly, a review of the relevant literature shows that tolerance to sub-anaesthetic doses of ketamine is largely unreported in neuropharmacological studies. METHODS: In order to investigate this caveat, we have performed a post hoc analysis of the behavioural effects induced by repeated injections of sub-anaesthetic doses of ketamine observed in five consecutive monkeys performing two oculomotor tasks. Ketamine effects were quantified by the animals' performances and latencies in a prosaccade and an antisaccade task, two oculomotor paradigms that are impaired after ketamine administration. RESULTS: Although the result of the initial injections confirmed a clear behavioural effect of ketamine injections in all monkeys, subsequent administrations showed that a tolerance eventually appeared in all monkeys. The profile of this tolerance exhibited however a large inter-subject variability. CONCLUSIONS: Psychopharmacological experiments using ketamine as a pharmacological model of psychosis should therefore consider the kinetic and time course of these effects in each individuals and take them into account in the design of experimental protocols.
BACKGROUND:Ketamine, a non-competitive N-methyl-D: -aspartic acid antagonist, has been widely used for anaesthetic purposes. At sub-anaesthetic dosage, it induces a dissociative state similar to schizophrenia. The discovery of this effect on dissociative state has led to its use as a pharmacological model of schizophrenia and has also been responsible for its illegal use as a recreational drug. Whereas the former has provided invaluable information, the latter has demonstrated that repeated administration of ketamine induces tolerance. Surprisingly, a review of the relevant literature shows that tolerance to sub-anaesthetic doses of ketamine is largely unreported in neuropharmacological studies. METHODS: In order to investigate this caveat, we have performed a post hoc analysis of the behavioural effects induced by repeated injections of sub-anaesthetic doses of ketamine observed in five consecutive monkeys performing two oculomotor tasks. Ketamine effects were quantified by the animals' performances and latencies in a prosaccade and an antisaccade task, two oculomotor paradigms that are impaired after ketamine administration. RESULTS: Although the result of the initial injections confirmed a clear behavioural effect of ketamine injections in all monkeys, subsequent administrations showed that a tolerance eventually appeared in all monkeys. The profile of this tolerance exhibited however a large inter-subject variability. CONCLUSIONS: Psychopharmacological experiments using ketamine as a pharmacological model of psychosis should therefore consider the kinetic and time course of these effects in each individuals and take them into account in the design of experimental protocols.
Authors: Ana Stefanovic; Brigitta Brandner; Elissa Klaassen; Roman Cregg; Mayavaty Nagaratnam; Lesley M Bromley; Ravi K Das; Susan L Rossell; Celia J A Morgan; H Valerie Curran Journal: J Clin Psychopharmacol Date: 2009-04 Impact factor: 3.153
Authors: Bruce I Turetsky; Monica E Calkins; Gregory A Light; Ann Olincy; Allen D Radant; Neal R Swerdlow Journal: Schizophr Bull Date: 2006-11-29 Impact factor: 9.306
Authors: Gary Gilmour; Elsa Y Pioli; Sophie L Dix; Janice W Smith; Michael W Conway; Wendy T Jones; Sally Loomis; Rebecca Mason; Shahram Shahabi; Mark D Tricklebank Journal: Psychopharmacology (Berl) Date: 2009-05-07 Impact factor: 4.530
Authors: Samantha A Gerb; Jemma E Cook; Alexandria E Gochenauer; Camille S Young; Lindak K Fulton; Andrew W Grady; Kevin B Freeman Journal: Comp Med Date: 2019-01-29 Impact factor: 0.982
Authors: Nolan R Williams; Boris D Heifets; Christine Blasey; Keith Sudheimer; Jaspreet Pannu; Heather Pankow; Jessica Hawkins; Justin Birnbaum; David M Lyons; Carolyn I Rodriguez; Alan F Schatzberg Journal: Am J Psychiatry Date: 2018-08-29 Impact factor: 18.112
Authors: Kristin E Killoran; Courtney A Walsh; Jennifer L Asher; Molly B Tarleton; Steven R Wilson Journal: J Am Assoc Lab Anim Sci Date: 2021-03-17 Impact factor: 1.232
Authors: Albert R Powers; Mark G Gancsos; Emily S Finn; Peter T Morgan; Philip R Corlett Journal: Psychopathology Date: 2015-09-12 Impact factor: 1.944
Authors: Priyodarshan Goswamee; Remington Rice; Elizabeth Leggett; Fan Zhang; Sofia Manicka; Joseph H Porter; A Rory McQuiston Journal: Neuropharmacology Date: 2022-01-20 Impact factor: 5.250